

Aetna Better Health®

Fax completed prior authorization request form to 844-802-1412 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at https://www.aetnabetterhealth.com/Illinois-medicaid

Opioids

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis

Member Information																		
Member Name (first & last):						Date of Birth:			G	ender	:			Height:				
] Male			☐ Femal			le				
Member ID:						City:	State:							Weig	nt:			
Prescribing Provider Informa	ation																	
Provider Name (first & last):						ty:		NPI#					DEA#					
Office Address:							State:					Zip Code:						
Office Contact:					Office Phone Offic						ce Fax:							
Dispensing Pharmacy Inform	ation			•														
Pharmacy Name:				Pharmacy Phone: Pharmacy Phone:						rmacy Fax:								
Requested Medication Inform	natio	n		ı					<u> </u>									
Preferred Short Acting						ascomp-	□ cc	□ codeine sulfate					□ r	norphir	e sı	ulfat	e IR	
Agents:					c	codeine												
	□ oxycodone] E	ndocet	□ tra	lol		Lorcet □ c			oxycodone-APAP					
		APAP-co	APAP-codeine															
Duefermed Learn Action		NA la ina a	C-14-1	- FD	45													
Preferred Long Acting Agents:		Morphine	Sultai	e EK	15m	g												
		Specify																
Non-Preferred Short Acting Ag																		
Non-Preferred Long Acting Ag	jent:	Specify	drug:															
Are there any contraindications to the preferred medications							□ Y€	es		No								
(if yes, please specify):												req	uest	_		est	erapy	
Directions for Use:						Strength:	l .				Dos	sage	Form:		<i>,</i> 40.			
						Quantity:	Day St	ınnlıv			Du	Duration of Therapy/Use:						
						Quaritity.	Day 30	дрргу.	•		Dui							
Medication request is NOT for		Diagnosis:					ICD-10 Code:											
compendia-supported diagnosis (circle one): Yes																		
No What medication(s) have been	triod	and failed	for thi	o dio	anac	ic? Diocco co	ooifv:											
what medication(s) have been	ıııeu	and raned	101 111	s uia	grios	sis: Flease sp	ecity.											
Turn-Around Time for Review	N																	
☐ Standard – (24 hours)		Urgent -	- If wai	ting 2	24 ho	ours for standa	ard deci	sion c	could	l seric	uslv	harn	n life. h	ealth. o	r ab	oility	to	
,						on, you can as							-,	, -		,		
		_				,,,												
		Signatur	e:															
Clinical Information																		
Pain is due to ONE of the following:		□ Activ	e Can	cer		Sickle Cell	☐ Palliative/End of life						Hosp	ice			N/A	
Will member be on both opioid	Ł	□ Yes		No	Wil	l Naloxone be	provide	d/off	ered	?			Yes		О		N/A	
AND benzodiazepine at same																		

time?																	
Is request for opioid naïve member?		Yes		No	ls	Is member opioid tolerant?						Yes		No		N/A	
Was non-pharmacologic therapy tried PRIOR to prescribing opioids (PT, exercise, CBT OR weight loss)?											Yes		No				
SNRIs OR anticonvulsants)										Yes		l No					
Signed treatment plan addresses the following (check that apply):	for p	Realistic goals r pain AND nction Realistic goals r pain AND treatment will be stopped Consequences of lost medication obtaining controlled substances from other prescribers											usir	dember ng ONE armacy			
respiratory depression, combination use with BNZ, risks to others in household, cognitive limitations AND side effects)?										□ Ye	□No						
										□ Yes		□ No					
Will treatment be reviewed within 1-4 weeks of starting opioid therapy for CHRONIC pain AND with any DOSE-										□ Yes		□ No					
ESCALATION AND RE-EVALUATED		<u> </u>															
Was there a review of the state's PI		rug Mo	onito	ring P	rogr									□ Yes		□ No	
Was UDS reviewed prior to starting			□ `	Yes				results of UDS o		vith p	ores	cribed	k	□ Ye	s	□ No	
treatment? Is there evidence of substance use			V					olled substances				/ 22		N.a		N/A	
disorder?			Yes		NO	MAT ari			nent like		Ш	□ Yes		No		N/A	
Is request for female of reproductive	/e		Yes	N	No			eling provided a	bout opioic	l		Yes		No □		N/A	
age?						use dur	ing	pregnancy AND	neonatal								
						abstine	nce	syndrome?									
Additional Clinical Information																	
Long Acting Opioids			Т		T							I					
Will member exceed 90 MME per day limit?											□ N/A						
day iii iii :		support exceeding recommended limit?															
Was pain specialist consulted?	□Y	'es		No										□ Y	□Yes □N		
Was treatment started with an IR o	l pioid	for at I	least	2 wee	eks p	orior to re	que	sting ER/LA opi	oid?	<u>.</u> !?					es	□ No	
Is request for buprenorphine		Yes		No	Is	there nee	ed fo	or opioid with lov	wer risk for	abu	se A	ND a		□Y	es	□ No	
weekly patch?					nc	ted conc	ern	that member O	R member'	s ho	useł	nold is	at				
					ris	k for abu	ıse A	AND diversion?									
Is request for non-preferred agent?		Yes		No		Was there inadequate response OR intolerance to MSER for at least 2 weeks?								□ Ye	□ No		
Is request for abuse-deterrent		Yes		No	4									□ Y	es	□ No	
product?						it least 2 weeks?											
						s there a NEED for abuse deterrent agent AND a noted								□ Ye	es	□ No	
						oncern the ND divers		nember OR hous ?	enola is at	risk	tor a	ıbuse					
Is request for methadone ?	□Y	'es		No				ber pregnant?	□ Yes			No			N/A	4	
☐ Short Acting Opioids					1												
Will member exceed 90 MME per		Yes	[□No				ocumentation to				□Y	es	□ □	No		
day limit?						necessity of exceeding recommended MME,										N/A	
Is request for non-preferred short-	+	Yes	or day supply limit? s □ No Was there inadequate response OR □ Yes								+	No					
acting agent?		- •						o 2 preferred sh									
						opioids?											
Was documentation submitted supporting continued use of a SHORT ACTING AGENT beyond 30 days AND ☐ Yes											No						
when used in combination with LOI																	
☐ Acute Pain Pediatric Member		s than	18 y	1								10					
Is request for ACUTE pain (post-de procedure)?					Yes		No	Was a pain ass		omp	lete	d?		□ Ye	es	□ No	
Were member AND their parent(s)	/guar	dian(s) scre	enec	d for	previous	ANI	D current opioid	use?	_	_	_	_	□Y€	es	□ No	

Has provider checked state's PMP Drug Monitoring Program for controlled substances?										□Yes	□ No			
Was concomitant use with BNZ appropriately addressed, if present? ☐ Yes ☐ No										□ N/A	A			
Was COMBO therapy of APAP	□Yes □ No ¹		No ۱	Will OPIOID	l in CO	МВО	□Yes	□ No						
AND failed OR there is C/I pres	?	with APAP and NSAIDs un					nless	there	is C/I					
·							oresent for u							
Is medication prescribed codeine or tramadol with age being <12 years?											□ No	□ N/A	4	
(NOTE: use of these medications is C/I in ages younger than 12 AND not recommended for ages														
12-17.)														
Will prescription be limited to 8 – 12 tablets?											□Yes	□ No		
Will IR opioids be prescribed, limited to lowest effective dose AND no quantity greater than expected pain duration											□Yes	□ No		
that is severe enough to require opioids will be given (NOTE: 3 days or fewer is recommended by CDC)?														
□ RENEWAL ONLY														
Was there sustained improven	nent in Pa	in OR		☐ Yes	;	□ No	Was taper	ing plan initi	ated t	0	☐ Yes	□ No		
Function?							D/C treatn	ment of curre	ent				N/A	
							medication	n?						
Was UDS performed in past ye	ar?			□Yes	;	□ No	•							
State's PMP was reviewed	other		Benzodia	azepine	□ ER / LA	[□ UDS	is consi	stent with	1				
AND verified (check that	provide	rs			use)		use for acute prescr			ibed con	trolled		
apply):								pain			nces			
Is dose ≥50 MME per day?	□Yes	□ No	Did provider offer Naloxone to member? ☐ Yes								□ No			
													N/A	
Is dose ≥90 MME per day?	☐ Yes	□ No	Did	Did provider refer member to Pain Specialist? ☐ Yes								□No		
			·										N/A	
Is there continued	☐ Yes	□ No	Was member counseled on FDA BBW on concomitant ☐ Yes ☐ No ☐											
concomitant use of opioid			use AND provider to prescribe at LOWEST effective dose										N/A	
with BNZ?			AND duration?											
Additional information the pr	escribing	provide	r feel	s is imp	orta	nt to thi	s review. P	lease speci	y bel	ow or	submit ı	medical ı	ecords	
Signature affirms that inform	otion =1	on on the		a io trese	اء س		to and safe	oto office	otos					
Signature amirms that inform	auon give	en on this	TOPI	ı is true	and	accura	ite and refle	CLS OITICE N	otes.					
Prescribing Provider's Signature: Date:														

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Standard turnaround time is 24 hours. You can call 866-329-4701 to check the status of a request.